Harrow, Inc. (HROW)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Mark L. Baum J.D. | CEO & Chairman of the Board | 1.2M | -- | 1972 |
| Mr. Andrew R. Boll C.F.A., C.M.A. | CFO & Corporate Secretary | 764.39k | -- | 1982 |
| Mr. John P. Saharek MBA | Chief Commercial Officer | 656.89k | -- | 1960 |
| Dr. Dennis E Saadeh Pharm.D. | Chief Scientific Officer | -- | -- | -- |
| Ms. Jamie Webb | Director of Communications & Investor Relations | -- | -- | -- |
| Mr. Brett A. Burrell | Vice President of Legal & Compliance | -- | -- | -- |
| Ms. Kim Barratt | Chief of Staff | -- | -- | -- |
| Dr. Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs & Pharmacovigilance | -- | -- | -- |
Harrow, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 315
Description
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Corporate Governance
Recent Events
- Mar 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 20, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 19, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 15, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 29, 2024SC 13G: Tender Offer/Acquisition ReportsSee Full Filing